EGFR and cancer: Fortunately, EGFR signal pathway can be blocked by small-molecule tyrosine kinase inhibitors (TKIs), including gefitinib and erlotinib, which targeting the EGFR to suppress cancer cell proliferation, invasion and metastases [19, 20].